Last checked at 
Oncimmune Holdings PLC - immunodiagnostics company - Signs two separate agreements with Roche Pharmaceuticals and Cedars-Sinai Medical Center, in each case to use its newly developed and proprietary Infectious Disease panel.
"As the world shifts its focus to recovering from the pandemic, we are seeing continued interest in Oncimmune's infectious disease offering," says Chief Executive Adam Hill. "We are also experiencing substantial interest in our immuno-oncology and autoimmune activities, which together with our infectious disease offering, provides us with confidence in the continued growth of ImmunoINSIGHTS."
Current stock price: 200.00 pence, up 5.3% on Tuesday
Year-to-date change: up 22%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
